Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia
Arsenic trioxide has become the treatment of choice for patients with
acute promyelocytic leukaemia. Cardiovascular toxicity is known to occur with
this therapy, in particular heart rhythm disorders due to QT interval prolongation.
We present a case of ventricular arrhythmia with no QT prolongation in a patient
receiving arsenic trioxide therapy.